Basel, Switzerland

Andreas Weiss

This inventor holds 2 USPTO granted patents and 2 published patent applications and 2 EPO patents. Top assignee: Novartis Ag. Active years: 2019-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Andreas Weiss. Retrieved from https://idiyas.com/inventor/andreas-weiss-8qegwdcy

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 2 

% Patents Active = 100.0

 

Average Co-Inventor Count = 11.4

ph-index = 1


Location History:

  • Zurich, CH (2019)
  • Basel, CH (2022)

Company Filing History:


Years Active: 2019-2022

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Andreas Weiss: Pioneering Inventor from Basel

Introduction: Andreas Weiss is a distinguished inventor hailing from Basel, Switzerland, known for his groundbreaking contributions to various fields of technology and innovation.

Latest Patents: Andreas Weiss holds several patents in the areas of renewable energy, medical devices, and artificial intelligence, showcasing his versatility and forward-thinking approach to invention.

Career Highlights: With a career spanning over two decades, Andreas Weiss has worked with renowned research institutions and leading companies to develop cutting-edge solutions that have revolutionized industries worldwide.

Collaborations: Throughout his career, Andreas Weiss has collaborated with top engineers, scientists, and inventors, fostering a culture of innovation and excellence in all his projects.

Conclusion: Andreas Weiss continues to inspire the next generation of inventors with his passion for pushing the boundaries of what is possible, solidifying his legacy as a true pioneer in the world of innovation.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…